Comprehensive and systematic review of economic evaluation literature of AF screening

Task 41 The development of a new decision analytic model including a variety of screening technologies with updated parameters of risks effects and costs Partners LIU MAC Duration months 1 24 Deliverables D41 42WP4s economic evaluations of screening programmes will assess the costs and consequences of broad management pathways encompassing the invitation and attendance to the screening tests interpretation of test results decision treatment or surveillance and implementation of chosen treatments In order to provide good value for money the cost of inviting an often large number of individuals to the screening tests must be reasonable in relation to the health benefits gained by treating a limited number of individuals Decisionanalytic modelling will be utilised to analyse this relationship in the costeffectiveness analyses of AFFECTEUs diverse screening programmes parameters will involve screening specific information such as attendance rates test characteristics decisionalteration parameters and the effect of implemented treatments themselves42 43 The decision analytic model will integrate data from WP1 WP2 WP3 which will provide new evidence on the stroke risk equation updated parameters on the prognosis of screendetected AF effectiveness and adherence of OAC treatment actual cost data for the different screening technologiesprocedures medical workup and longterm cost and effects of AF related complications including QoL Our new model will be informed by the finding in AFFECTEU and a systematic literature review and in addition to thromboembolic events also include other preventable AF comorbidities eg heart failure myocardial infarction and dementia The information on QoL available in all studies of the proposal will be integrated into the model improving the estimation of QoL in different screening strategiesWP2 results will permit other testsbiomarkersgenetics to enter the economic modelling which has the potential of improving the prognostic value of the screening strategies as well as the costeffectiveness due to better patient selection